Our greatest passion is learning from patients and partnering with them to capture and share their expertise with professionals in the healthcare system, in particular industry, payers, and HCPs.
Advanced Therapy Medicinal Products: why patient engagement is even more important than in “traditional” therapies
While patient engagement from early development through market access to patient access is becoming more and more a standard in the pharmaceutical industry, it is even more important in cell-, gene, and organ replacement therapies (so-called ATMPs).
Rare Diseases Run 2023
admedicum, together with friends (family, collaborators, clients), participated in the 2nd edition of the Rare Diseases Run in Aachen, Amsterdam, and Cologne.
Understanding roles and best practices of patient involvement in Health Technology Assessment
Listen to Thomas Smith, Life Sciences Public Engagement Specialist, and Dr. Andreas Reimann, Managing Partner and Co-Founder of admedicum discussing patient engagement in Health Technology Assessment (HTA) processes. Their conversation focused on how patients can interact at the right time with HTA processes to ensure the patients’ best interests are covered in areas like patient-relevant data, access to new treatments, and affordability.